Physician profile
Alan B Marks
NPI 1942270145
$3,977.02
in general payments reported to CMS, 2019-2025
26 companies · $962 in 2025
The $962 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $131 · 2021: $438 · 2022: $612 · 2023: $495 · 2024: $806 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.53 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $474.39 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $396.85 | 2021-2025 | Simbrinza, Clareon |
| Bausch & Lomb Americas INC. | $389.88 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $301.01 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $277.03 | 2019-2022 | |
| Glaukos Corporation | $232.30 | 2019-2025 | Idosetr |
| Harrow Eye, LLC | $230.79 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $207.76 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $202.91 | 2019-2024 | Cequa |
| Dompe US, INC. | $173.74 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $170.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $150.88 | 2019-2023 | |
| Genentech USA, INC. | $125.00 | 2023 | Vabysmo |
| Amgen INC. | $113.74 | 2024-2025 | Tepezza |
| Allergan, INC. | $86.42 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $80.93 | 2022 | |
| Aerie Pharmaceuticals, INC. | $80.24 | 2019-2021 | |
| Thea Pharma INC. | $64.41 | 2023-2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $44.79 | 2019-2020 | |
| Shire North American Group INC | $44.43 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $33.80 | 2023-2024 | Catalys System, Amo Phaco Needle, Veritas Vision System |
| Sight Sciences, INC. | $21.45 | 2022 | |
| Biotissue Holdings INC. | $20.73 | 2019 | |
| Ocular Therapeutix, INC. | $18.47 | 2023 | Dextenza |
| Rxsight INC | $17.64 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Abb Con-Cise Optical Group LLC | $17.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.